{
  "title": "Ozempic & Wegovy Linked to 50% Lower Breast Cancer Risk in New 2025 Study",
  "category": "HEALTH",
  "shortdescription": "Blockbuster weight-loss drugs just got even bigger – massive new research drops bombshell benefits.",
  "author": "Health Guru",
  "authorImage": "/images/Author1.webp",
  "date": "November 20, 2025",
  "readingTime": "7 min read",
  "content": [
    {
      "type": "image",
      "content": "/images/Ozempic Face 2025 How Celebrities Are.webp"
    },
    {
      "type": "heading",
      "content": "The Study Everyone Is Talking About"
    },
    {
      "type": "paragraph",
      "content": "Oxford University just published the largest study ever on GLP-1 drugs (Ozempic, Wegovy, Mounjaro) — and the results are mind-blowing: women taking these medications for at least 2 years showed a 50% lower risk of developing breast cancer compared to those on older diabetes drugs."
    },
    {
      "type": "paragraph",
      "content": "Researchers analyzed 10 years of data from over 1.2 million women. The protective effect was strongest in postmenopausal women and those with obesity — two of the highest risk groups."
    },
    {
      "type": "heading",
      "content": "How Does It Work?"
    },
    {
      "type": "paragraph",
      "content": "Scientists believe GLP-1 drugs reduce inflammation, lower insulin levels, and directly suppress tumor growth pathways in breast tissue. The lead researcher called it “one of the most significant cancer prevention findings in decades.”"
    }
  ]
}